Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

Leiomyoma Clinical Trial

Official title:

An Open Label, Dose Escalation Study to Assess Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) in Subjects With Uterine Leiomyoma (Fibroids)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02889848
• Other study ID #: FIB1154
• Status: Completed
• Phase: Phase 1
• Start date: October 27, 2016
• Est. completion date: November 15, 2018

Study information

• Verified date: June 2018
• Source: Advance Biofactures Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot study evaluates the safety and tolerability of a single injection of collagenase enzyme directly into a uterine fibroid in subjects already selected for hysterectomy or myomectomy.

Fibroids contain excessive amounts of collagen and it is possible that digestion of collagen may be beneficial in reducing pain and bleeding associated with fibroids.

Three subjects will be injected with saline only to evaluate the safety and effectiveness of the injection method. Additional subjects will then be injected with increasing doses of study drug.

Description:

Collagenase enzyme breaks down collagen and has shown efficacy in clinical trials for a number of diseases for which there is an accumulation of collagen.

It is possible that lysis of collagen may reduce the collagen content of fibroids thus decreasing the size of fibroids, and possibly reducing the stiffness of fibroids. This may result in reducing the symptoms of pain and bleeding associated with fibroids.

In this study three subjects will be injected with saline only followed immediately by hysterectomy in order to evaluate the safety and effectiveness of the injection method.

Twelve subjects will receive a single injection of study drug as follows: three subjects will receive a set dose of collagenase enzyme followed by hysterectomy or myomectomy 24-96 hours later (Group 1) to evaluate safety of the injection of study drug. Nine subjects will then receive increasing doses of collagenase enzyme followed by hysterectomy or myomectomy 60-90 days later (Group 2).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: November 15, 2018
• Est. primary completion date: October 5, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 35 Years to 50 Years

Eligibility

Inclusion Criteria:

• Parous and non-parous women who have completed child-bearing (age criteria of > 35 years-old, and <50 years-old)

• Currently practicing or willing to practice contraception throughout the duration of the study

• Women with at least one or two fibroids greater than or equal to 3 cm diameter, and less than or equal to 10 cm diameter for subjects in Group 1, and at least one fibroid greater than or equal to 3 cm diameter, and less than or equal to 10 cm diameter for subjects in Group 2

• Fibroids will be intramural fibroids which will be surrounded by a layer of myometrium. Fibroids must be well visualized on ultrasound examination and provide a clear path for injection

• Women who were planning to undergo abdominal hysterectomy or myomectomy for treatment of symptomatic fibroids. Subjects must be willing to defer the operation until 24-96 hours after study treatment for Group 1 and for 60-90 days after study treatment for Group 2. The patients will understand that they may choose to have surgery or any other non-study treatment at any time after enrollment and end study participation

• "Typical" large fibroids visualized as hypo-intense on a T2-weighted MRI scan

Exclusion Criteria:

• Inability to understand study procedures or to comply with study visits and requirements

• BMI > 40kg/m2

• History of allergic reaction to study medication (Collagenase Clostridium Histolyticum) or any components of the study drug

• Inability to undergo hysterectomy or myomectomy

• Inability to tolerate MRI and transvaginal ultrasound procedures (i.e. presence of an intra-uterine device (IUD), pacemakers, aneurismal clips or other metallic devices that are not compatible with magnetic resonance imaging). However women with IUD's compatible with MRI are eligible for the study

• Medical problems including: genetic diseases that cause fibroids, history of thromboembolic (blood clot) events or need for anticoagulation (Coumadin, Heparin, etc.) Subjects taking or planning to take anti-coagulant medication (except for = 150 mg aspirin daily) within 7 days administration study drug and within 7 days before and after hysterectomy

• A history of cancer within the past 5 years

• Abnormal liver function tests (typically, will be >20% elevation). Mild elevations will be at the discretion of the investigators, but undiagnosed liver conditions will represent an exclusion criterion

• Pregnancy or lactation. Pregnancy will be evaluated by urine test every 30 days if necessary. Patients will be asked to use non-hormonal contraception methods while in this study

• Severe anemia (hematocrit <30). Mild anemia is common in women with fibroids

• Recent rapid growth of fibroids (i.e. doubling in size within one-six months period)

• Any use of agents like Imidazoles, due to possible interference with metabolism

• Unevaluated gynecologic abnormalities (unexplained vaginal bleeding, cervical dysplasia, or abnormal adnexal/ovarian mass)

• Fibroids that are visualized on T2 and T1 weighted MRI as hyperdense or show cystic degeneration

• Inability to undergo injection of fibroid with study drug for any reason, anatomic or other

• Has a known systemic allergy to collagenase or any other excipient of EN3835 or any other procedural medication

• Has, at any time, received collagenase as a treatment

• Is planning to be treated with commercial XIAFLEX at any time during the study

• Type 0 submucosal fibroids, submucosal fibroids with significant protrusion/ pedunculation and subserosal fibroids are not appropriate candidates for the injections

Related Conditions & MeSH terms

• Fibroids, Uterine
• Leiomyoma

Intervention

Other:
• Saline
Saline injection

Drug:
• EN3835
Comparison of maximum marketed dose and multiple doses EN3835

Locations

Country	Name	City	State
United States	Johns Hopkins Hospital	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Advance Biofactures Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events following a single injection of EN3835 into a fibroid	Assessed by number of subjects with uterine injury or peritoneal irritation determined post hysterectomy	Through hysterectomy or myomectomy (average = 60-90 days post injection)
Secondary	Change in symptoms of pain and bleeding and quality of life	Determined by standardized questionnaires for menstrual distress, quality of life and sexual activity; McGill Pain Questionnaire	Throughout the study prior to hysterectomy or myomectomy(avg 60-90 days post injection study drug)
Secondary	Reduction in size of treated fibroids- Group 2	Size of fibroid to be determined post hysterectomy or myomectomy	60-90 days post injection study drug
Secondary	Increased rate of apoptosis of treated fibroids -Group 2	Specimens to be taken post hysterectomy or myomectomy and evaluated by TUNEL staining	60-90 days post injection study drug
Secondary	Reduction in collagen content of treated fibroids-Group 2	Specimens to be taken post hysterectomy or myomectomy and by tested histology stains	60-90 days post injection study drug
Secondary	Reduction in stiffness of treated fibroid-Group 2	Specimens to be taken post hysterectomy or myomectomy and tested via rheometry	60-90 days post injection study drug